PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene

N. P. Johnson, A. W. Stewart, J. Falkiner, C. M. Farquhar, S. Milsom, V.- P. Singh, Q. L. Okonkwo, K. L. Buckingham
2010 Human Reproduction  
background: Ovulation induction treatment with metformin, either alone or in combination with clomiphene citrate (CC), remains controversial even though previous randomized trials have examined this. methods: A double blinded multi-centre randomized trial was undertaken including 171 women with anovulatory or oligo-ovulatory polycystic ovary syndrome. Women with high body mass index (BMI) . 32 kg/m 2 received placebo ('standard care') or metformin; women with BMI ≤ 32 kg/m 2 received CC
more » ... received CC ('standard care'), metformin or both. Treatment continued for 6 months or until pregnancy was confirmed. Primary outcomes were clinical pregnancy and live birth. results: For women with BMI . 32 kg/m 2 , clinical pregnancy and live birth rates were 22% (7/32) and 16% (5/32) with metformin, 15% (5/33) and 6% (2/33) with placebo. For women with BMI ≤ 32 kg/m 2 , clinical pregnancy and live birth rates were 40% (14/35) and 29% (10/35) with metformin, 39% (14/36) and 36% (13/36) with CC, 54% (19/35) and 43% (15/35) with combination metformin plus CC. conclusions: There is no evidence that adding metformin to 'standard care' is beneficial. Pregnancy and live birth rates are low in women with BMI . 32 kg/m 2 whatever treatment is used, with no evidence of benefit of metformin over placebo. For women with BMI ≤ 32 kg/m 2 there is no evidence of significant differences in outcomes whether treated with metformin, CC or both.
doi:10.1093/humrep/deq100 pmid:20435692 fatcat:e25q6j4thvc6rozf527rp76bx4